674 people on the Nipah contact list in Kerala
Out of these, 131 are from Malappuram, 426 from Palakkad, 115 from Kozhikode, and one each from Ernakulam and Thrissur districts, Health Minister Veena George said.
She said "84 people removed from the contact list after completing isolation. In Malappuram, 12 individuals are undergoing treatment in isolation."
So far, 88 samples from the district have tested negative. After completing their isolation period, 81 people from Malappuram, two from Palakkad, and one from Ernakulam have been removed from the contact list. Currently, 17 people in Palakkad are under isolation treatment.
Across the state, 32 individuals are under highest-risk surveillance, while 111 are in the high-risk category.
The minister also directed the One Health Centre for Nipah Research to document all matters related to Nipah cases. An ICMR team visited Malappuram for inspection yesterday.
A high-level meeting was convened under the leadership of Minister Veena George on Thursday. Officials including the NHM State Mission Director, Director of the Health Department, Director of Medical Education, Additional Directors, District Collectors, District Medical Officers, police officials, and officers from various departments participated in the meeting.
UNI DS RKM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
36 minutes ago
- United News of India
Over 4,300 thalassemia patients registered in portal; Majority under age 12: Govt in RS
New Delhi, July 29 (UNI) As many as 4,361 thalassemia patients have been registered on the National Sickle Cell Portal, with children below the age of 12 accounting for a significant share ie 2,579 cases, data shared by the Union Ministry of Health and Family Welfare today in the Rajya Sabha revealed. Responding to a written question in this regard, Union Minister of State for Health and Family Welfare Anupriya Patel stated that a dedicated thalassemia module was integrated into the Sickle Cell Portal in 2023. The module enables States and Union Territories to systematically upload patient records, thereby facilitating regular monitoring, follow-ups, and data-driven surveillance on a national scale. The Minister noted that while the overall responsibility for thalassemia-related management and public awareness lies with respective State and UT governments, the Centre continues to extend support under the National Health Mission (NHM). This includes both financial and logistical assistance aimed at strengthening public health infrastructure. 'Support is provided for a range of services, including screening and treatment, provision of medicines, blood bank facilities, day care centres, laboratory services, training of healthcare personnel, and Information, Education and Communication (IEC) activities,' Patel said. These measures are incorporated into the Programme Implementation Plans submitted annually by States and UTs, she added. Highlighting ongoing efforts to improve access to advanced treatment, the Minister also referred to the Thalassemia Bal Sewa Yojana (TBSY), an initiative supported by Coal India Limited under its Corporate Social Responsibility (CSR) mandate. The scheme provides financial assistance of up to Rs10 lakh for bone marrow transplants (BMT) in eligible patients, and is currently operational across 17 empanelled hospitals nationwide. UNI AJ SSP
The Hindu
2 hours ago
- The Hindu
SB43154 drug used in cancer research shows promise against COVID-19 in preclinical studies: Scientists
After a long battle and research, Indian scientists have found out that a drug used in cancer studies has the potential to provide substantial protection against the coronavirus infection in preclinical studies. Remarkably, even after more than 50 consecutive generations exposed to the drug, the virus was unable to develop resistance. Scientists from the Indian Council of Medical Research (ICMR) and Indian Council of Agricultural Research (ICAR) have jointly found that the drug -- SB431542, an ALK5 inhibitor -- is highly effective against the coronavirus. Study findings This discovery was a collaborative effort between the National Centre for Veterinary Type Culture in Hisar and National Institute of Virology (NIV) under the ICMR in Pune, said NIV Director Dr Naveen Kumar. The study was first released as a preprint on bioRxiv and has since been accepted for publication in the Journal of Virology. If future human trials confirm its effectiveness, the drug could become a groundbreaking tool in the fight against COVID-19. Since December 2019, when the coronavirus emerged from China's Wuhan, it has spread to nearly every country in the world. Since 2020, more than 30 anti-Covid vaccines have received the World Health Organization's (WHO) approval for global use. "However, health experts believe vaccines alone are not enough. The virus continues to mutate, and many existing treatments like Remdesivir and monoclonal antibodies will quickly lose effectiveness," Kumar said. In this context, Indian scientists have been screening small molecule inhibitors that mainly target cellular kinases and phosphatases. One such compound, SB431542 -- originally developed to block TGF-β (Transforming Growth Factor-beta) signalling and commonly used in preclinical cancer, inflammation and fibrosis research -- has now been found by Indian researchers to also inhibit the coronavirus effectively. Kumar explained that SB431542 fights the virus in three fronts. It first blocks the virus from entering human cells by targeting the TGF-β/Smad pathway. Secondly, it disrupts the ability of the virus to assemble inside cells by interfering with ORF3a-related lysosomal dysfunction. Finally, it prevents the virus from killing the infected cell (a process called apoptosis), which helps stop the virus from escaping and spreading to other cells. This three-pronged approach has not been observed in any existing antiviral drug. Interestingly, the drug acted through both direct and indirect mechanisms -- it directly targets the viral ORF3a protein and indirectly hinders the virus by blocking the host cell's TGF-β signaling pathway. SB431542 was also tested against the chicken coronavirus (Infectious Bronchitis Virus or IBV) in specific pathogen-free chicken embryos. Embryos treated with the drug developed normally and showed no mortality, while those in the untreated control group failed to develop properly and did not survive. Kumar emphasised that even after exposing the virus to the drug over 50 successive generations (passage), it failed to develop resistance. This suggests that the chances of the virus evolving a drug-resistant variant against this compound are extremely low. This is a major advancement over existing antivirals like Remdesivir, against which the virus builds resistance quickly.
India Today
5 hours ago
- India Today
Kerala to give HPV vaccines to Class 11, 12 students to prevent cervical cancer
In a major public health initiative, the Kerala Health Department has decided to administer the Human Papillomavirus (HPV) vaccine to Plus One and Plus Two students across the state to prevent cervical cancer. Health Minister Veena George announced the plan following a high-level meeting held under her vaccine, which is most effective when administered between the ages of 9 and 14, can be given up to the age of 26. The final decision on the rollout will be taken in a technical committee meeting scheduled within a week. Minister Veena George said the move is in line with the Chief Minister's directive to work towards a cervical cancer-free cancer is one of the most common cancers affecting women, and the HPV vaccine is considered a key preventive measure. To ensure effective implementation, the state will also launch an awareness campaign tailored for both students and their parents. Special messaging will be developed as per the recommendations of the technical committee and delivered at the school level. The vaccination drive is part of a broader cancer prevention strategy in the state. Kerala has already formed a cancer care grid to coordinate diagnosis and treatment services. In addition, the state recently launched the campaign 'Arogyam Anandam Akattam Arbudam', through which over 17 lakh people have been screened so Health Department aims to build awareness and ensure wide participation in the vaccination drive, taking another step towards eliminating cervical cancer in Kerala.- Ends IN THIS STORY#Kerala
